Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

11.68 +0.13 (+1.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd

< Previous 1 2 3 4 5 6 7 8 Next >
Where Roivant Sciences Stands With Analysts
Via Benzinga
Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate
Via Benzinga
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker
From Roivant Sciences
Via GlobeNewswire
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
Analyst Ratings for Roivant Sciences
Within the last quarter, Roivant Sciences (NASDAQ:ROIV) has observed the following analyst ratings: 
Via Benzinga
Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases
Via Benzinga
Why Roivant Sciences' Shares Are Up Thursday
The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis. 
Via The Motley Fool
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
From Roivant Sciences
Via GlobeNewswire
Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90%
Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt analyst Barton Crockett maintained a Neutral rating on the stock. Pinterest shares rose 2% to $24.91 in... 
Via Benzinga
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
  Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday. 
Via Benzinga
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
From Roivant Sciences
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. 
Via Benzinga
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
Via Benzinga
Roivant Sciences Announces Proposed Public Equity Offering
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
From Roivant Sciences
Via GlobeNewswire
Tilray Brands, Canopy Growth, Cronos Group And Other Big Gainers From Thursday
U.S. stocks closed lower with the Dow Jones dropping more than 300 points on Thursday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday. 
Via Benzinga
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
Via Benzinga
Expert Ratings for Roivant Sciences
  Over the past 3 months, 4 analysts have published their opinion on Roivant Sciences (NASDAQ:ROIV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding... 
Via Benzinga
JELD-WEN, Royal Caribbean Cruises And Some Other Big Stocks Moving Lower On Monday
  FiscalNote Holdings Inc. (NYSE: NOTE) fell 22.7% to $6.43. FiscalNote closed its earlier-announced agreement to acquire Aicel Technologies. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
Earnings Scheduled For June 28, 2022
Companies Reporting Before The Bell • Jupai Hldgs (NYSE:JP) is projected to report earnings for its first quarter. 
Via Benzinga
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
From Pfizer Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.